SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

A project grown out of the community's love and passion for the weed culture. Launched around early 2025, $weedcoin, “Like Bitcoin but way higher,” emphasizes its alignment with cannabis culture and a laid-back vibe. Unlike other Weed communities, this project leans heavily into community engagement over technical utility, aiming to build a “stoner community” through social media presence and decentralized governance. We also aim to focus on onboarding web2 businesses and users onto web3 through the token.

Weedcoin

Weedcoin is trending with strong community focus on the upcoming 4/20 event, as supporters champion its identity as the "culture coin" for the cannabis ecosystem, touting its long-term growth potential and current outperformance against traditional cannabis stocks.

Sunrun, Inc. engages in the design, development, installation, sale, ownership, and maintenance of residential solar energy systems. It sells solar service offerings and installs solar energy systems for homeowners. Customers can access its products through three channels: direct-to-consumer, solar partnerships, and strategic partnerships. The company was founded by Edward Harris Fenster, Robert Nat Kreamer, and Lynn Michelle Jurich in January 2007 and is headquartered in San Francisco, CA.

Sunrun Inc

Sunrun is experiencing a significant stock plunge after its Q4 earnings report, where robust revenue beats were overshadowed by weaker-than-expected 2026 cash flow guidance and declining growth metrics. This has ignited intense community debate, with many investors believing the sell-off is an overreaction and an opportunity to buy the dip, while others foresee continued downward pressure in the volatile solar sector.

Red Cat Holdings, Inc. provides products, services and solutions to the drone industry. It also engages in the provision of distributed data storage, analytics and services for the drone industry.The firm product include Dronebox, which is a blockchain technology that records, stores and analyzes flight data and information from a drone. It operates through the Enterprise Segment. The Enterprise Segment will focus on developing a hardware enabled software platform of services and solutions to government and commercial enterprises and the military. The company was founded by Jeffrey M. Thompson in February 1984 and is headquartered in San Juan, Puerto Rico.

Red Cat Holdings Inc

Red Cat Holdings is trending as investors weigh insights from its Innovation Day and await crucial results from the Drone Dominance Program, where its FANG and Black Widow drones are competing for significant defense contracts. The community is actively discussing the company's long-term potential in defense technology, including its uncrewed surface vessels, against a backdrop of global defense spending, despite ongoing concerns about immediate profitability and stock volatility.

Equinox Gold Corp. is a growth-focused mining company, which engages in the exploration of gold mining properties. It operates through the following segments: Greenstone, Mesquite, Castle Mountain, Los Filos, Aurizona, Fazenda, RDM, Santa Luz, and Corporate. The company was founded by Marc Pais on March 23, 2007, and is headquartered in Vancouver, Canada.

Equinox Gold Corp

Equinox Gold is trending following the strategic sale of its Brazil operations for over $1 billion, a move largely seen as strengthening its balance sheet and focusing on North American growth with the recent first gold pour at its Greenstone Mine. Community discussion highlights analyst upgrades and high expectations for the company to achieve major gold producer status, despite some past frustration over share price performance.

Infleqtion, Inc. engages in delivering neutral atom solutions for quantum computing, networking, sensing, and security. Its products are categorized into computing, sensing, and cores. The company was founded on February 7, 2007, and is headquartered in Louisville, CO.

Infleqtion Inc. - Ordinary Shares - Class A

Infleqtion Inc.

Infleqtion is trending as investors highlight its significant role in NASA's quantum gravity mission and strategic collaborations with NVIDIA, fueling community debate over its neutral-atom technology's market advantage and substantial undervaluation compared to quantum sector peers, despite recent post-SPAC volatility.

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

ImmunityBio Inc

ImmunityBio is trending as community discussion intensifies around CEO Dr. Patrick Soon-Shiong's recent high-profile interviews, which have highlighted compelling patient testimonials for Anktiva's cancer-curing potential and its broader applications in longevity, fueling debate over perceived regulatory roadblocks from established pharmaceutical interests and the potential for a significant short squeeze.

GSI Technology, Inc. engages in the design, development and marketing of memory products primarily for the networking, and telecommunications markets. Its product includes Static Random Access Memory, or SRAM, which incorporated in networking and telecommunications equipment, such as routers, switches, wide area network infrastructure equipment, wireless base stations and network access equipment. It also offers services to the ongoing needs of the military, industrial, test and measurement equipment, automotive and medical markets for SRAMs .The company was founded by Lee-Lean Shu and Robert Yau in March 1995 and is headquartered in Sunnyvale, CA.

GSI Technology Inc

GSIT is seeing heated discussion following its preliminary benchmark announcement for the Gemini-II AI chip, which proponents highlight for its edge AI efficiency and defense potential, while a significant portion of the community alleges misleading claims and market manipulation by the company and its promoters.

Amprius Technologies, Inc. engages in the development, manufacture, and market lithium-ion batteries for mobility applications, including the aviation, electric vehicle and light electric vehicle industries. It operates through the United States and Rest of the World geographical segments. The company was founded by Mark C. Platshon in 2008 and headquartered in Fremont, CA.

Amprius Technologies Inc

Amprius Technologies is trending following fresh analyst upgrades with significant price targets and a strategic U.S. manufacturing partnership for its high-performance silicon anode batteries. The community is keenly focused on the company's pivotal role in the burgeoning drone and defense industries, where its superior battery technology is seen as a necessity for extended mission capabilities.

ProShares Trust - ProShares VIX Short-Term Futures ETF

ProShares VIX Short-Term Futures ETF

ProShares VIX Short-Term Futures ETF (VIXY) is trending as traders position for heightened market volatility, fueled by escalating geopolitical tensions and renewed threats of global tariffs. The community is actively discussing hedging strategies against perceived market complacency and the potential for significant downturns.

Zscaler, Inc. engages in the provision of a cloud-based internet security platform. It offers Zero Trust Exchange, Zscaler Client Connector, Zscaler Internet Access, Zscaler Private Access, Zscaler B2B, Zscaler Cloud Protection, and Zscaler Digital Experience. The company was founded by Jagtar Singh Chaudhry and K. Kailash in September 2007 and is headquartered in San Jose, CA.

Zscaler Inc

Zscaler is trending due to a significant stock drop following its Q2 earnings report, which, despite beating estimates and raising full-year guidance, revealed an increased GAAP net loss. The market is weighing concerns over profitability and valuation within the broader software and cybersecurity sector's "AI disruption" narrative, leading to sharp community division between those calling the sell-off irrational and a buying opportunity, and those highlighting persistent losses.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>The deal includes an initial five-year term and may automatically renew for another five years if performance targets are met.</li><li>The licensing agreement is expected to deliver immediate scale and revenue as soon as it goes into effect.&nbsp;</li><li>The expanded portfolio is expected to strengthen Tilray’s distributor relationships and broaden national chain offerings.</li></ul>Tilray Brands, Inc. (TLRY) on Wednesday announced that it has secured exclusive rights to brew, market, and distribute several Carlsberg beer brands across the U.S. beginning in 2027.Tilray is a diversified global consumer goods company and the fourth-largest craft beer brewer in the U.S.<h2 class="st-heading-2">Expanding U.S. Beer Presence</h2>The multi-year licensing agreement with the Danish brewing giant will allow Tilray to produce and distribute Carlsberg, Carlsberg Elephant, 1664, and Kronenbourg 1664 Blanc beers in all U.S. channels starting Jan. 1, 2027.&nbsp;The deal includes an initial five-year term and may automatically renew for another five years if performance targets are met. Tilray will use its brewing facilities, sales teams, and commercial networks to locally make and grow the market reach of these imported beers.&nbsp;Following the announcement,&nbsp;<a href="https://stocktwits.com/symbol/TLRY">Tilray Brands’ stock&nbsp;</a>traded over 4% higher by Wednesday mid-morning.&nbsp;<h2 class="st-heading-2">Strategic Benefits For Tilray</h2>The licensing agreement is expected to deliver immediate scale and revenue as soon as it goes into effect.&nbsp;<blockquote>“By combining Carlsberg’s iconic global brands and proven brewing heritage with Tilray Beverages’ U.S. operational scale, quality standards, and national commercial team, we are well positioned to expand Carlsberg’s presence in the premium European segment and drive long-term growth in the U.S. beer market.”-Irwin D. Simon, Chairman and CEO, Tilray</blockquote>This expanded portfolio may help strengthen Tilray’s distributor relationships, broaden national chain offerings, and enhance its standing in the U.S. beverage category.<h2 class="st-heading-2">How Did Stocktwits Users React?&nbsp;</h2>On Stocktwits, retail sentiment around the stock jumped to ‘bullish’ from ‘bearish’ territory the previous day. Message volume changed to ‘high’ from ‘low’ levels in 24 hours.&nbsp;<figure class="image"><img src="https://news.stocktwits-cdn.com/Screenshot_2026_02_18_112750_png_7df23c56bf.webp" alt="TLRY’s Sentiment Meter and Message Volume as of 11:20 a.m. ET on Feb. 18, 2026 | Source: Stocktwits" width="935" height="110"><figcaption>TLRY’s Sentiment Meter and Message Volume as of 11:20 a.m. ET on Feb. 18, 2026 | Source: Stocktwits</figcaption></figure>A bullish Stocktwits user lauded the partnership.<stembedurl>https://stocktwits.com/Alexsolstice/message/645225129</stembedurl>&nbsp;TLRY stock has declined by over 12% in the last 12 months.&nbsp;Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/moderna-stock-fda-accepts-revised-flu-vaccine-application-for-review/cZR0MwoR4v1">Moderna Stock Gains After FDA Accepts Company’s Revised Flu Vaccine Application For Review</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, a Tilray Brands logo is seen displayed on a smartphone and in the background.

Tilray To Produce And Distribute Carlsberg Beer Brands In US – Stock Gains 4%

The multi-year licensing agreement with the Danish brewing giant will allow Tilray to produce and distribute several Carlsberg beer brands in all U.S. channels starting Jan. 1, 2027. 

Equity

The multi-year licensing agreement with the Danish brewing giant will allow Tilray to produce and distribute several Carlsberg beer brands in all U.S. channels starting Jan. 1, 2027. 


<ul class="summary-bullets"><li>Tilray’s Q2 revenue rose 3% to $217.5 million, beating estimates of $211.5 million, according to Fiscal.ai data</li><li>The management reaffirmed its fiscal 2026 adjusted EBITDA outlook of $62 million to $72 million.</li><li>Tilray is currently operating at an annualized run rate of about $150 million, CEO Irwin D. Simon told analysts on a call on Thursday.</li></ul>Tilray Brands (TLRY) stock gave up most of its early gains to trade about 2.5% higher on Friday after Alliance Global slashed its price target on the stock, pointing to limited visibility into the company’s long-term sales trajectory and cash flow following its second-quarter (Q2) fiscal 2026 results.Analyst Aaron Grey reduced Tilray’s target price to $10 from $20 while maintaining a ‘Neutral’ rating. He said the quarter came in largely in line at the consolidated level, with “some strengths offsetting some weaknesses,” but the firm stayed on the sidelines, looking for clearer insight into the company’s sales and cash flow outlook.<h2 class="st-heading-2">Q2 Print</h2>Tilray’s second-quarter (Q2) revenue rose 3% to $217.5 million, beating estimates of $211.5 million, according to Fiscal.ai data. The revenue increase was driven by a 36% jump in international medical cannabis sales. Net loss narrowed to $43.5 million from $85.3 million a year earlier.Operating cash flow remained negative, though it narrowed to $8.5 million compared to $40.7 million last year. The firm’s management reaffirmed its fiscal 2026 adjusted earnings before interest, tax, depreciation, and amortization (EBITDA) outlook of $62 million to $72 million, citing long-term opportunities tied to U.S. cannabis rescheduling and medical expansion.Chairman and CEO Irwin D. Simon told analysts on a call on Thursday that Tilray is currently operating at an annualized run rate of about $150 million, driven mainly by international markets. Simon also added that Europe, particularly Germany, the U.K., and Poland, represents a significant growth opportunity.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Despite the intraday gains, retail sentiment on Stocktwits for <a href="https://stocktwits.com/symbol/TLRY">TLRY</a> remained in the ‘bearish’ territory over the past 24 hours.<figure class="image"><img src="https://news.stocktwits-cdn.com/TLRY_jpg_463814541d.webp" alt="TLRY.jpg" width="922" height="96"><figcaption>&nbsp;</figcaption></figure>However, some users were bullish, with one highlighting Tilray’s strong results.<stembedurl>https://stocktwits.com/Mlitton13/message/641317326</stembedurl>The stock has declined 24% over the past year.Read also: <a href="https://stocktwits.com/news-articles/markets/equity/why-oklo-stock-surged-premarket-today-meta-deal/cmU2fX3R4dI">OKLO Stock Surged 20% In Premarket Today – What’s The Meta Agreement About?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

TLRY Stock In Focus After Alliance Global Halves Price Target

Alliance Global cut TLRY’s target price to $10 from $20, citing limited visibility into the company’s long-term sales trajectory and cash flow.

Cannabis ETFs Soar Double-Digits on Friday: Here's Why

Cannabis ETFs explode on reform buzz. CNBS, WEED, MSOS and MJ jumped double-digits on Dec. 12, 2025 as Trump reportedly weighs reclassifying marijuana, boosting optimism.

Cannabis plants grow in the greenhouse at Vireo Health's medical marijuana cultivation facility, August 19, 2016 in Johnstown, New York. (Photo by Drew Angerer/Getty Images)

Trump Moves A Step Closer To Reclassifying Marijuana As A Less Dangerous Drug — A Breakout Moment For Weed Industry?

The cannabis industry is enjoying renewed momentum under Trump, whose administration has adopted a notably more accommodative approach toward the drug and its related products.

<ul class="summary-bullets"><li>Bloomberg reported that the Centers for Medicare &amp; Medicaid Services (CMS), which runs the Medicare program, is planning an initiative that would make some U.S. Medicare patients eligible for CBD coverage.&nbsp;</li><li>MSOS and YOLO, two key cannabis sector-focused funds, gained 3.4% and 2.7%, respectively.</li><li>The Trump administration seems to be backing cannabis as an industry, following its previous comments regarding CBD and reclassifying marijuana.</li></ul>Cannabis&nbsp;stocks advanced on Wednesday following a report speculating that certain U.S Medicare patients could soon be eligible to receive coverage for CBD under a new initiative.CBD, or cannabidiol, is a compound found in cannabis and used to treat sleep disorders, anxiety, pain, and inflammation. Some research suggests it may also treat cancer symptoms. The drug is sold as gummies, pet treats, and skincare supplements.<h2 class="st-heading-2">Cannabis Stocks Rally</h2>Tilray Brands’ shares rose 4.8%, while the over-the-counter stocks of Curaleaf Holdings, Trulieve Cannabis, and Green Thumb Industries gained between 2% to 5.6%. Shares of Innovative Industrial Properties, a real estate investment trust (REIT) that buys and leases specialized cannabis cultivation facilities, rose 1.1%.On Stocktwits, the retail sentiment for&nbsp;<a href="https://stocktwits.com/symbol/TLRY">TLRY</a> shifted to ‘extremely bullish’ from ‘bullish,’ while that for&nbsp;<a href="https://stocktwits.com/symbol/CURLF">CURLF</a> shifted to ‘bullish’ from ‘neutral.’ The sentiment was ‘bullish’ for&nbsp;<a href="https://stocktwits.com/symbol/GTBIF">GTBIF</a>, and ‘bearish’ for&nbsp;<a href="https://stocktwits.com/symbol/GTBIF">TCNNF</a> and&nbsp;<a href="https://stocktwits.com/symbol/IIPR">IIPR</a> as of the last reading.&nbsp;The&nbsp;<a href="https://stocktwits.com/symbol/MSOS">AdvisorShares Pure US Cannabis ETF (MSOS)</a>, which tracks U.S. cannabis companies exclusively, and the&nbsp;<a href="https://stocktwits.com/symbol/YOLO">AdvisorShares Pure Cannabis ETF (YOLO)</a>, which also tracks overseas companies and cannabis-adjacent businesses, rose 3.4% and 2.7%, respectively.<h2 class="st-heading-2">CMS Initaitive</h2>The rally came after Bloomberg&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.bloomberg.com/news/articles/2025-11-26/medicare-to-test-making-cbd-treatment-available-for-seniors">reported</a> that the Centers for Medicare &amp; Medicaid Services (CMS) is planning an initiative that would make some U.S. Medicare patients eligible for CBD coverage.&nbsp;Details of the proposed program aren’t available, but an early version of the plan focused on seniors in oncology and palliative care settings, according to a summary viewed by the news agency.Unnamed sources told Bloomberg that Howard Kessler, a payments financier who has advocated for expanded CBD access, met with Health and Human Services Secretary Robert F. Kennedy Jr. about the issue last month<h2 class="st-heading-2">A Trump Boost?</h2>The development comes close on the heels of President Donald Trump highlighting the potential benefits of cannabidiol in senior healthcare. Hemp-derived cannabidiol (CBD) could "revolutionize senior healthcare" by slowing disease progression and serving as an alternative to prescription drugs, Trump had&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/tilray-canopy-growth-cannabis-stocks-lose-high-premarket-after-surge-triggered-by-trumps-post/chDDTJ9R3BB">said</a> in a video post in September.The previous month, Trump said his administration was weighing a move to reclassify marijuana as a less dangerous drug under federal law.That said, doubts over cannabis efficacy in healthcare remain. A&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2836267">recent study</a> funded by the Food and Drug Administration suggested that prolonged use of CBD may cause liver toxicity, while other research suggests it can interfere with other medications, harm male reproductive health, and pose potential risks to children and pregnant women.For updates and corrections, email newsroom[at]stocktwits[dot]com.Read Next:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/holiday-shopping-could-soar-to-a-record-1-trillion-this-year-with-online-spending-blasting-to-new-highs/cL5eLqVREW6">Holiday Shopping Could Soar To A Record $1 Trillion This Year, With Online Spending Blasting To New Highs</a>

Tilray, IIPR, Trulieve, Other Cannabis Stocks Rally On Report Of Government Considering Adding CBD Treatment For Medicare Patients  

The development comes close on the heels of President Donald Trump highlighting the potential benefits of cannabidiol in senior healthcare. 

The Zacks Analyst Blog Highlights MSOS, CNBS, WEED, MJ and YOLO

Zacks Analyst Blog highlights MSOS, CNBS, WEED, MJ, and YOLO as marijuana ETFs soar over 100% in three months on U.S. legalization hopes and investor optimism.

From Loss to Lift-Off: Marijuana ETFs Rebound on Legalization Prospects 

Marijuana ETFs, such as WEED, MSOS, and CNBS, are rebounding as hopes for rescheduling boost investor optimism. 

Top-Performing ETFs of Last Week

ETFs tied to cannabis, Ethereum and Chinese tech stocks topped last week's winners list. Top performers were KSTR, YOLO, ARKZ, CHIQ and CNXT.

Cannabis ETFs Soar as Trump Mulls Over Marijuana Reclassification

Cannabis ETFs like WEED, CNBS and MJ surge after Trump confirmed that his administration is weighing marijuana's move from Schedule I to Schedule III.


Nasdaq-listed shares of Canopy Growth Corp. (CGC) fell 12% in pre-market trading on Friday after the cannabis company <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.canopygrowth.com/investors/news-releases/canopy-growth-reports-fourth-quarter-and-fiscal-year-2025-financial-results/">reported</a> wider-than-expected fourth-quarter (Q4) loss.The company’s fourth quarter revenue fell 11% year-on-year (YoY) to C$65.03 million ($47.16 million), below an analyst estimate of C$70.87 million, according to Finchat data.The company attributed the drop to a decline in net revenue from its international markets cannabis, and Storz &amp; Bickel segments.In Canada, cannabis net revenue was C$40 million in the quarter, marking an increase of 4% YoY. However, across international markets, the revenue declined 35% YoY to C$8 million, owing to a decline in medical cannabis sales in Poland and Australia, the company said.Storz and Bickel, meanwhile, delivered net revenue of C$17 million in the quarter, a decrease of 23% YoY, owing to softer consumer demand for its devices. Storz and Bickel designs vaporizers for combustion-free vaporization and inhalation of dry herbs.The company’s gross margin fell by 500 basis points to 16% in the quarter, and it reported an adjusted loss before interest, taxes, depreciation, and amortisation (EBITDA) of C$9 million. Analysts had only expected a loss of C$3.13 million.The company’s total debt, however, decreased to C$304 million as of March 31, compared to C$597 million on the corresponding date of 2024.The company said on Friday that it plans to continue to focus on accelerating growth in global medical cannabis, improving commercial execution, and profitability in Canada’s adult-use cannabis market. The company also said that cost actions are underway and it expects annualized savings of at least C$20 million over the next 12 to 18 months.CFO Judy Hong also said that the company is committed to achieving positive adjusted EBITDA in the “near-term,” without specifying a timeline.On Stocktwits, retail sentiment around Canopy Growth stayed within the ‘bearish’ territory over the past 24 hours while message volume rose from ‘normal’ to ‘high’ levels.<figure class="image"><img style="aspect-ratio:627/64;" src="https://news.stocktwits-cdn.com/Screenshot_2025_05_30_at_8_59_37_AM_png_cf8cb9e0cf.webp" alt="CGC's Sentiment Meter and Message Volume as of 8:15 a.m. ET on May 30, 2025 | Source: Stocktwits" width="627" height="64"><figcaption>CGC's Sentiment Meter and Message Volume as of 8:15 a.m. ET on May 30, 2025 | Source: Stocktwits</figcaption></figure> A Stocktwits user termed the Q4 earnings reports “a pretty big let down.” &nbsp;<stembedurl>https://stocktwits.com/JustAGlitchBTMFD/message/616291899</stembedurl><a href="https://stocktwits.com/symbol/CGC">CGC stock </a>is down by about 41% this year and by about 80% over the past 12 months.Read Next: <a href="https://stocktwits.com/news-articles/markets/equity/zymeworks-drug-gets-conditional-approval-for-biliary-tract-cancer-in-china/ch0Mun4RbMx">Zymeworks’ Drug Gets Conditional Approval For Biliary Tract Cancer Treatment In China: Retail Sentiment Refuses To Budge</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.(Exchange Rate: I Canadian Dollar= 0.73 US Dollar)

A cart full of bagged marijuana is rolled through the corridors at the Canopy Growth Corporation headquarters in Smiths Falls, Ontario, on May 15, 2019. (Photo by Lane Turner/The Boston Globe via Getty Images)

Canopy Growth Stock Drops Pre-Market After Disappointing Q4 Earnings: Retail Terms It ‘A Pretty Big Let Down’

CFO Judy Hong said the company is committed to achieving positive adjusted EBITDA in the “near-term,” without specifying a timeline.

Advisorshares Trust - AdvisorShares Pure Cannabis ETF

Day trading

Swing trading

Long-term investing

Sitting in cash

Markets have been volatile, with macro headlines and earnings driving sharp moves. How are you positioning right now?

Drop your approach below 👇

YOLO
AdvisorShares Pure Cannabis ETF

Feed

News

Sentiment

Fundamentals

Info

Poll

Latest YOLO News

YOLOAdvisorShares Pure Cannabis ETF